Dogwood Therapeutics, Inc.
$ 1.80
3.14%
07 Aug - close price
- Market Cap 60,701,000 USD
- Current Price $ 1.80
- High / Low $ 1.80 / 1.76
- Stock P/E 1.49
- Book Value 2.41
- EPS 1.21
- Next Earning Report 2026-08-12
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.19 %
- ROE -0.35 %
- 52 Week High 9.50
- 52 Week Low 1.28
About
Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company is headquartered in Alpharetta, Georgia.
Analyst Target Price
$14.00
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-14 | 2026-03-18 | 2025-11-06 | 2025-08-13 | 2025-05-08 | 2025-02-26 | 2024-11-07 | 2024-08-08 | 2024-05-09 | 2024-02-29 | 2023-11-13 | 2023-08-10 |
| Reported EPS | -0.15 | -0.26 | -8.2 | -1.99 | -8.45 | -6.29 | -2.05 | -1.25 | -1.75 | -0.06 | -1.5 | -2 |
| Estimated EPS | -0.2 | -0.86 | -1.58 | -1.9 | -0.76 | -0.0567 | -1.18 | -1.58 | -1 | -0.06 | -2.25 | -1.25 |
| Surprise | 0.05 | 0.6 | -6.62 | -0.09 | -7.69 | -6.2333 | -0.87 | 0.33 | -0.75 | 0 | 0.75 | -0.75 |
| Surprise Percentage | 25% | 69.7674% | -418.9873% | -4.7368% | -1011.8421% | -10993.4744% | -73.7288% | 20.8861% | -75% | 0% | 33.3333% | -60% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-12 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.13 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: DWTX
2026-07-22 14:09:58
Virios Therapeutics Inc. (VIRI) is cautiously trading after a reverse stock split and continues to explore strategic options amidst financial constraints in 2024. The biotechnology company, focused on developing treatments for chronic diseases triggered by herpes viruses like fibromyalgia, has reported a net loss and modest cash reserves. Its enterprise value is tied to future trial results and licensing opportunities rather than current earnings.
2026-07-08 02:09:54
Virios Therapeutics is evaluating strategic options while focusing its clinical development on fibromyalgia and related conditions. The company, a clinical-stage biotechnology firm, specializes in antiviral-based therapies for chronic pain and fatigue, particularly fibromyalgia, and emphasizes well-structured clinical trials to advance its pipeline. Its ability to secure funding and establish partnerships will be crucial for the long-term success and commercialization of its therapies.
2026-06-16 14:40:17
Virios Therapeutics (VIRI) is a micro-cap biotech focused on treating fibromyalgia, with its stock performance heavily influenced by quarterly earnings and cash burn rates. As the company has no approved products, investor focus remains on R&D expenses, administrative costs, and the cash runway to fund clinical trials for its lead candidate IMC-1. The company's future value depends on generating positive clinical data to support a regulatory submission, making operational updates and clinical milestones crucial for investor sentiment.
2026-06-06 13:40:48
This article provides details of an EDGAR Form 8-K filing (SEC Accession No. 0001558370-24-013167) filed by Virios Therapeutics, Inc. The filing date was October 7, 2024, with a period of report ending October 4, 2024. It covers various items, including material definitive agreements, acquisition/disposition of assets, equity security sales, security holder rights modifications, officer changes, and amendments to organizational documents, listing multiple exhibits and graphic files.
2026-06-01 23:39:14
This page provides a detailed stock quote and company information for Dogwood Therapeutics Inc (DWTX), including its current stock price, financial metrics, insider and institutional ownership, and recent performance. It also lists significant news events and announcements related to the company, highlighting its progress in clinical trials and corporate developments.
2026-05-04 22:39:49
This article provides a detailed stock analysis of Virios Therapeutics Inc. (VIRI), a development-stage biotechnology company, including its current share price, market capitalization, key financial ratios, and performance metrics. It highlights the company's focus on developing antiviral therapies for conditions like fibromyalgia and long COVID. The report also includes peer comparisons and answers frequently asked questions about the stock.
